Navigation Links
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Date:10/23/2007

of EpCAM in cancer stem cell regulation.

"All of these new findings correlate well together and highlight the prospects of EpCAM-directed immunotherapies," commented Carsten Reinhardt, M.D., Chief Medical Officer of Micromet. "While the findings from our collaborators in Munich may finally explain the well-known negative prognostic potential of EpCAM, the clinical data on adecatumumabs potential inhibitory effect on new metastases provide a clear rationale for moving forward into early-stage cancer settings where the goal is prevention of disease re- occurrence rather than palliative shrinkage of large tumor bulk."

All of the above cited abstracts can be viewed on the AACR website at http://www.aacr.org.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the first antibody developed using the BiTE(R) technology platform to be clinically validated in Micromet's product pipeline, is being evaluated in a phase 1 clinical trial for the treatment of patients with non- Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono, a division of Merck KGaA in Darmstadt, Germany, in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical
'/>"/>

SOURCE Micromet, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. Olympics of biotechnology has international flavor
3. Traffic data firm navigates international business
4. Catalyst International profit exceeds expectations
5. Lack of broadband hamstrings international videoconferencing
6. 30 days to success: Three simple steps to create your own international startup
7. TEKLYNX International announces new RFID software
8. Ruling enforces international trademark electronic filing requirements
9. Eleftheriou to lead Catalyst International
10. Internet trademark war goes international
11. International eyes drawn to Madisons games research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... 2014 In contrast to traditional LED ... various colors, Valoya uses proprietary LED technology to incorporate ... possible uniformity which is critical in low proximity installations. ... accuracy throughout its lifetime which is up to four ... , "The investment cost was clearly higher when compared ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... CAMBRIDGE, Mass., Dec. 17 Genzyme Corp.,(Nasdaq: ... and Drug Administration,(FDA) has approved a supplemental indication ... in combination with radioiodine to ablate,or destroy, the ... their,cancerous thyroids removed. Remnant ablation is a procedure ...
... GENEVA, Switzerland, Dec. 17 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... of,Dr. Cameron Durrant to its Board of Directors. ... Global Strategic Marketing at Johnson,& Johnson (NYSE: ... privileged to welcome Dr. Durrant to our,Board," said ...
... England, December 17 , - New Deal ... its,Therapeutic Antibody Pipeline, Oxford Genome Sciences (UK) ... a strategic collaboration with Amgen to discover, develop ... cancer.,This new collaboration will enable OGeS to further ...
Cached Biology Technology:Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4Anavex strengthens Board of Directors 2Anavex strengthens Board of Directors 3Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... professor of medicine at National Jewish Health, has ... lipids and related compounds that can inhibit inflammation ... by influenza and respiratory syncytial virus (RSV). Over ... several scientific papers describing a naturally occurring lipid ...
... bunch of inanimate chemical compounds, the nucleic and amino acids ... have put on quite a soap opera for biologists since ... A new study, a highlight in the March issue of ... In TV listings the series would be described this ...
... considered to be the principle vectors of West Nile virus ... summer. In addition, these mosquitoes may also serve as overwintering ... mosquito to egg, then larva, and then adult. To ... in mosquitoes in the field and in the lab, and ...
Cached Biology News:Does the villainous 'selfish' gene undermine genome's police? 2Does the villainous 'selfish' gene undermine genome's police? 3West Nile virus passes from female to eggs, but less so from larvae to adults 2
... with PowerPac 3000 power supply, 220-240 V, ... by liquid-phase isoelectric focusing (IEF). The system ... standard (60 ml) focusing chambers, chassis, harvesting ... power supply, 10 ml Bio-Lyte ampholytes (pH ...
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
... Chromogen system consists of [5-Bromo-4-Chloro-3-,Indolyl ... a single component,solution. The ready-to-use ... presence of alkaline phosphatase to ... minimal background noise. ,The System ...
... microplate readers combines reagent dispensing with fluorescence, ... easy-to-use platform for the complete range of ... and adaptability of the Infinite 200 series ... monochromator (M200) or filter (F200) system and ...
Biology Products: